Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Analytical Method Development: Deviation Management during Method Development – V 2.0

Posted on By

Analytical Method Development: Deviation Management during Method Development – V 2.0

SOP for Deviation Management during Analytical Method Development Activities


Department Analytical Method Development
SOP No. SOP/AMD/031/2025
Supersedes SOP/AMD/031/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP describes the procedure for managing deviations that occur during analytical method development activities. It ensures proper identification, documentation, investigation, impact assessment, and closure in compliance with current Good Manufacturing Practices (cGMP) and quality system requirements.

2. Scope

This SOP applies to all deviations observed during analytical method development activities including experimental errors, procedural lapses, equipment malfunctions, and data anomalies within the AMD department.

3. Responsibilities

  • Analytical Scientist: Identifies and documents deviations immediately; initiates preliminary investigation.
  • Team Lead: Reviews deviation details and supports root cause analysis and CAPA recommendations.
  • QA: Reviews, categorizes, and approves the deviation record; ensures compliance and closure.
  • Head – AMD: Approves deviation disposition and oversees any required rework, retraining, or documentation changes.
See also  Analytical Method Development: Selection of Mobile Phase for Chromatographic Techniques - V 2.0

4. Accountability

The Head of AMD is accountable for ensuring timely documentation, investigation, and resolution of all method development-related deviations in accordance with the site quality system and applicable regulatory guidelines.

5. Procedure

5.1 Deviation Identification

  1. Deviations may include:
    • Missed procedural steps (e.g., wrong pH buffer used)
    • Instrument malfunction during run
    • Improper documentation
    • Outlier data points with unexplained causes
  2. Analyst must report and document the deviation using Annexure-1: Deviation Reporting Form within 24 hours of occurrence.

5.2 Deviation Classification

  1. QA and Team Lead jointly classify the deviation as:
    • Minor: No significant impact on method outcome or GMP compliance.
    • Major: Affects critical parameters or may lead to rework.
    • Critical: Affects data integrity, regulatory filing, or results in potential non-compliance.
  2. Classification to be recorded in Annexure-2: Deviation Classification Log.

5.3 Investigation and Root Cause Analysis

  1. Use structured RCA tools (Fishbone Diagram, 5 Whys).
  2. Identify whether deviation arose from:
    • Human error
    • Equipment failure
    • Documentation issue
    • Material or reagent problem
  3. Record findings in Annexure-3: Root Cause Investigation Form.
See also  Analytical Method Development: Method Lifecycle Management - V 2.0

5.4 Impact Assessment

  1. Evaluate the impact on:
    • Development outcomes
    • Validation readiness
    • Regulatory submission timelines
  2. Define impact level (Low/Medium/High) and document in Annexure-4: Impact Assessment Sheet.

5.5 Corrective and Preventive Actions (CAPA)

  1. CAPA should address both immediate correction and long-term prevention.
  2. Actions may include:
    • Re-training
    • Instrument maintenance
    • Document revision
    • Procedural changes
  3. Document in Annexure-5: CAPA Implementation Tracker.

5.6 Deviation Closure

  1. QA to review investigation and CAPA implementation.
  2. If acceptable, deviation is marked “Closed” and documented in Annexure-6: Deviation Closure Record.
  3. Closed deviation records to be archived with traceable index for audit readiness.

6. Abbreviations

  • AMD: Analytical Method Development
  • CAPA: Corrective and Preventive Action
  • QA: Quality Assurance
  • RCA: Root Cause Analysis
  • GMP: Good Manufacturing Practices

7. Documents

  1. Deviation Reporting Form – Annexure-1
  2. Deviation Classification Log – Annexure-2
  3. Root Cause Investigation Form – Annexure-3
  4. Impact Assessment Sheet – Annexure-4
  5. CAPA Implementation Tracker – Annexure-5
  6. Deviation Closure Record – Annexure-6

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • WHO TRS 996 – Quality Risk Management
  • US FDA 21 CFR Part 211 – Subpart J: Records and Reports
See also  Analytical Method Development: Forced Degradation Studies - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Deviation Reporting Form

Date Analyst Method Code Description of Deviation
12/05/2025 Rajesh Kumar AMD/UV/062 Used wrong buffer concentration in mobile phase

Annexure-2: Deviation Classification Log

Deviation ID Type Classification Remarks
DEV/AMD/2025/017 Procedural Major Deviation from protocol

Annexure-3: Root Cause Investigation Form

Cause Identified Tool Used RCA Summary
Human Error 5 Whys Untrained staff used incorrect stock

Annexure-4: Impact Assessment Sheet

Impact Area Level Justification
Method Development Outcome Medium Trial required repetition

Annexure-5: CAPA Implementation Tracker

CAPA Action Owner Due Date Status
Re-training on buffer preparation Sunita Reddy 15/05/2025 Completed

Annexure-6: Deviation Closure Record

Deviation ID Closure Date Closed By QA Approval
DEV/AMD/2025/017 17/05/2025 Vinay Pawar Approved

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded impact assessment and included RCA formats Audit recommendation
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for Genetic Stability Testing – V 2.0
Next Post: API Manufacturing: SOP for LOD Testing During Drying Stage – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version